Study data showed treatment with Mydayis significantly improved ADHD symptoms, as assessed by the ADHD-RS-IV and the Permanent Product Measure of Performance (PERMP), in both adolescents and adults.

Shire nabbed FDA approval for its new long-acting ADHD drug, becoming the second drugmaker in two days to win a nod in that field. Shire’s drug, Mydayis, has been a long time coming. Previously known ...

A survey of patients with ADHD showed that two-thirds of those who augment their morning medication do so because it stops working, and 42% have to plan their day around their medication fading.

Despite earlier this month announcing it’s considering a sale of ADHD offerings, Shire has launched its latest Adderall formulation in the U.S. The company on Monday started selling Mydayis at a price ...

The US Food and Drug Administration (FDA) has approved a long-acting medication for attention-deficit/hyperactivity disorder (ADHD) from Shire called Mydayis (mixed ...

An estimated 4.4 percent of adults have Attention Deficit Hyperactivity Disorder (ADHD) in the U.S. — which means that when applied to the full U.S. adult population aged 18 and over, approximately 10 ...

Generic Mydayis extended-release capsules are a central nervous system stimulant prescription medicine used for the treatment of ADHD in people 13 years of age and older. Teva is offering ...

Shire PlcSHPG announced that the FDA has approved its new attention deficit hyperactivity disorder (ADHD) drug, Mydayis (mixed salts of a single-entity amphetamine product) in patients 13 years and ...

Shire Debuts MYDAYIS® and New Research at the 30th Annual Psych Congress Lexington, MA - September 15, 2017-Shire plc (LSE: SHP, NASDAQ: SHPG) will share new Attention Deficit Hyperactivity Disorder ...